miR-15a and miR-20b sensitize hepatocellular carcinoma cells to sorafenib through repressing CDC37L1 and consequent PPIA downregulation

Sorafenib is a classical targeted drug for the treatment of advanced hepatocellular carcinoma (HCC), but intrinsic resistance severely limited its therapeutic effects. In the present study, we aimed to identify crucial genes in HCC cells that affect sorafenib resistance by a CRISPR/Cas9 genome-scale...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Yu, Shijun, Chen, Jingde, Quan, Ming, Gao, Yong, Li, Yandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237098/
https://www.ncbi.nlm.nih.gov/pubmed/35760798
http://dx.doi.org/10.1038/s41420-022-01094-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237098/
https://www.ncbi.nlm.nih.gov/pubmed/35760798
http://dx.doi.org/10.1038/s41420-022-01094-2

Ejemplares similares